Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.  

Stepping stones
Alexion is taking steps to add further indications to its next-generation complement inhibitor • Source: Shutterstock

Alexion Pharmaceuticals Inc.'s progress in developing a next-generation successor for its aging blockbuster, Soliris (eculizumab) are being viewed in a positive light by analysts, who have been upbeat about late-stage clinical results released earlier this week involving the longer-acting successor, Ultomiris, in a second potential indication.

Top-line data from a Phase III study of Ultomiris (ravulizumab-cwvz) in complement-inhibitor naive patients with atypical hemolytic uremic syndrome (aHUS),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone

 
• By Urtė Fultinavičiūtė

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod

 
• By Alaric DeArment

US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.

Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III

 
• By Jessica Merrill

The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

 
• By Jessica Merrill

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.